Company Oramed Pharmaceuticals Inc.

Equities

ORMP

US68403P2039

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.92 USD +3.55% Intraday chart for Oramed Pharmaceuticals Inc. +4.29% +26.41%

Business Summary

Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Solutions
100.0 %
3 100.0 % 1 100.0 % -50.43%

Sales per region

USD in Million2022Weight2023Weight Delta
Israel
100.0 %
3 100.0 % 1 100.0 % -50.43%

Managers

Managers TitleAgeSince
Founder 83 02-04-11
Chief Executive Officer 50 02-04-11
Chief Operating Officer 53 13-04-13
Director/Board Member 59 07-10-22
Investor Relations Contact - -
General Counsel - 22-01-08

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 50 02-04-11
Founder 83 02-04-11
Director/Board Member 59 07-10-22
Director/Board Member 67 19-12-04
Director/Board Member 40 23-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,519,160 35,968,836 ( 88.77 %) 0 88.77 %

Shareholders

NameEquities%Valuation
1,955,070 4.847 % 6 M $
1,598,285 3.962 % 5 M $
BML Capital Management LLC
3.127 %
1,261,559 3.127 % 4 M $
Murchinson Ltd.
2.603 %
1,050,000 2.603 % 3 M $
763,666 1.893 % 3 M $
Boothbay Fund Management LLC
1.301 %
525,001 1.301 % 2 M $
481,833 1.194 % 2 M $
366,500 0.9086 % 1 M $
Jess S. Morgan & Co., Inc.
0.9083 %
366,401 0.9083 % 1 M $
Renaissance Technologies LLC
0.8455 %
341,073 0.8455 % 1 M $

Company contact information

Oramed Pharmaceuticals, Inc.

1185 Avenue of the Americas 3rd Floor

10036, New York

+844 967 2633

http://www.oramed.com
address Oramed Pharmaceuticals Inc.(ORMP)